The Endocannabinoid System and its Modulation by Phytocannabinoids
暂无分享,去创建一个
[1] L. Petrocellis,et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. , 1998, European journal of pharmacology.
[2] M. Cascio,et al. The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice , 2010, British journal of pharmacology.
[3] A. Akopian,et al. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. , 2009, Trends in pharmacological sciences.
[4] L. Petrocellis,et al. Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels , 2010, Journal of Neuroimmune Pharmacology.
[5] L. Petrocellis,et al. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation , 2012, Acta physiologica.
[6] D. Ponde,et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide , 2001, British journal of pharmacology.
[7] M. Abood,et al. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. , 2013, Life sciences.
[8] A. Kambalyal,et al. Endocannabinoids Anandamide and 2-Arachidonoylglycerol Are Substrates for Human CYP2J2 Epoxygenase , 2014, Journal of Pharmacology and Experimental Therapeutics.
[9] V. D. M. A. L. D. Petrocellis. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010 .
[10] V. Marzo,et al. Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.
[11] L. Steardo,et al. Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement , 2014, Phytotherapy research : PTR.
[12] V. Vellani,et al. Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8 , 2008, Journal of Pharmacology and Experimental Therapeutics.
[13] L. Petrocellis,et al. Why do cannabinoid receptors have more than one endogenous ligand? , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.
[14] R. Pertwee,et al. Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist , 2005, British journal of pharmacology.
[15] V. Di Marzo,et al. Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review , 2015, British journal of pharmacology.
[16] J. Walker,et al. Regulation of anandamide tissue levels by N-arachidonylglycine. , 2002, Biochemical pharmacology.
[17] D. Kendall,et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors , 2004, British journal of pharmacology.
[18] S. Popoff,et al. The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55 , 2012, Journal of Neuroimmune Pharmacology.
[19] D. Piomelli,et al. The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.
[20] L. Petrocellis,et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. , 2001, The Biochemical journal.
[21] Atsushi Inoue,et al. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. , 2006, Biochemical and biophysical research communications.
[22] I. Yamamoto,et al. Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis , 2008, Drug Metabolism and Disposition.
[23] A. Eschalier,et al. Monoacylglycerols Activate TRPV1 – A Link between Phospholipase C and TRPV1 , 2013, PloS one.
[24] S. Petrosino,et al. The anti‐inflammatory mediator palmitoylethanolamide enhances the levels of 2‐arachidonoyl‐glycerol and potentiates its actions at TRPV1 cation channels , 2016, British journal of pharmacology.
[25] D. Julius,et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.
[26] M. Hellmich,et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia , 2012, Translational Psychiatry.
[27] S. Hjorth,et al. The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.
[28] T. Hutchinson,et al. TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons , 2008, The Journal of Neuroscience.
[29] B. Watkins,et al. The endocannabinoid system: directing eating behavior and macronutrient metabolism , 2015, Front. Psychol..
[30] C. Russo,et al. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide , 2013, British journal of pharmacology.
[31] H. Bradshaw,et al. The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways , 2009, BMC Biochemistry.
[32] B. Birnir,et al. Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists* , 2005, Journal of Biological Chemistry.
[33] Benjamin J. Whalley,et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. , 2014, ACS chemical neuroscience.
[34] A. Saghatelian,et al. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. , 2006, Biochemistry.
[35] Stephen P. H. Alexander. Common Receptors for Endocannabinoid-Like Mediators and Plant Cannabinoids , 2015 .
[36] S. O'Sullivan,et al. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.
[37] K. Mackie,et al. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors. , 1995, Molecular pharmacology.
[38] Stephen P. H. Alexander,et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. , 2007, British journal of pharmacology.
[39] M. Cascio,et al. New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. , 2007, Journal of medicinal chemistry.
[40] E. Brǎiloiu,et al. Activation of GPR18 by cannabinoid compounds: a tale of biased agonism , 2014, British journal of pharmacology.
[41] M. Correia,et al. Characterization of cannabidiol-mediated cytochrome P450 inactivation. , 1993, Biochemical pharmacology.
[42] K. Verhoeckx,et al. Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. , 2011, Biochimica et biophysica acta.
[43] J. Lanciego,et al. CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum , 2014, Experimental Neurology.
[44] R. Pertwee,et al. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .
[45] V. Di Marzo,et al. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors , 2001, FEBS letters.
[46] Pierangelo Geppetti,et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[47] J. Renger,et al. Cross-Modulation and Molecular Interaction at the Cav3.3 Protein between the Endogenous Lipids and the T-Type Calcium Channel Antagonist TTA-A2. , 2014, Molecular Pharmacology.
[48] M. Connor,et al. Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol* , 2008, Journal of Biological Chemistry.
[49] Marc G Caron,et al. Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands* , 2009, The Journal of Biological Chemistry.
[50] L. Steardo,et al. Effect of cannabidiol on sepsis‐induced motility disturbances in mice: involvement of CB1 receptors and fatty acid amide hydrolase , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[51] G. Ahern. Activation of TRPV1 by the Satiety Factor Oleoylethanolamide* , 2003, Journal of Biological Chemistry.
[52] R. Pertwee. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. , 2008, British journal of pharmacology.
[53] T. Bisogno,et al. Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes* , 1997, The Journal of Biological Chemistry.
[54] V. Di Marzo,et al. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010, Current medicinal chemistry.
[55] L. Petrocellis,et al. Fifty years of ‘cannabinoid research’ and the need for a new nomenclature , 2014 .
[56] T. Bisogno,et al. Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes , 2011, British journal of pharmacology.
[57] T. Bisogno,et al. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.
[58] V. Di Marzo,et al. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. , 2007, Experimental cell research.
[59] Stephen P. H. Alexander,et al. Cannabinoid activation of PPARα; a novel neuroprotective mechanism , 2007 .